Diabetes Research Review, Issue 103

In this issue:

How does empagliflozin reduce CV mortality?
Real-world flash glucose monitoring
Glargine 300 vs. 100 U/mL in type 1 diabetes
Dulaglutide added to SGLT-2 inhibitor in inadequately controlled type 2 diabetes
Long-term renal outcomes of intensive glycaemic control
Type 1 diabetes incidence in China
Lifestyle intervention and medical management ±gastric bypass in type 2 diabetes
Long-term sustainability of diabetes prevention approaches
Cancers attributable to diabetes and high BMI
CV safety and efficacy of evolocumab

Please login below to download this issue (PDF)